Immediate Impact

1 from Science/Nature 84 standout
Sub-graph 1 of 19

Citing Papers

Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials
2024 Standout
Allergic Rhinitis
2024 Standout
3 intermediate papers

Works of Mark H. Moss being referenced

Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial
2021
Omalizumab pretreatment prevents allergic reactions due to rush immunotherapy (RIT)
2005
and 1 more

Author Peers

Author Last Decade Papers Cites
Mark H. Moss 1294 1126 188 24 1.4k
E. Helen Ramsdale 1556 1410 351 24 1.9k
M.R. Sears 1708 1263 407 13 2.0k
Michael Mellon 1395 1093 499 27 2.0k
Mona Palmqvist 1604 1386 415 35 1.9k
Stephen J. Langley 1502 1289 326 28 1.9k
Jonathan Matz 1375 1069 612 17 1.5k
Carin Jorup 1785 1701 197 30 2.0k
Marzena Krawiec 1535 1394 242 23 1.8k
Luz A. Froehlich 971 855 350 16 1.5k
Christina Keen 914 878 122 25 1.2k

All Works

Loading papers...

Rankless by CCL
2026